Intrathecal administration of rituximab for treatment of central nervous system lymphomas

Details for Australian Patent Application No. 2001259142 (hide)

International Classifications

Event Publications

11 November 2004 Assignment before Grant

IDEC Pharmaceuticals Corporation The application has been assigned to Biogen Idec Inc.

11 November 2004 Change of Name(s) of Applicant(s), Section 104

Idec Pharmaceuticals Corporation The name of the applicant has been changed to Biogen Idec Inc.

9 March 2006 Application Accepted

Published as AU-B-2001259142

29 June 2006 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 01 Jun 2006. Address for service in Australia - Davies Collison Cave 1 Nicholson Street MELBOURNE VIC 3000

6 July 2006 Standard Patent Sealed

23 November 2006 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 01 Jun 2006

18 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.